- Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference
- Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film
- Aquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ET
- Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology
- Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
- Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock
- Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock
- Aquestive Therapeutics Announces Proposed Public Offering of Common Stock
- Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting
More ▼
Key statistics
On Friday, Aquestive Therapeutics Inc (AQST:NMQ) closed at 3.09, 146.92% above the 52 week low of 1.25 set on Oct 06, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.38 |
---|---|
High | 3.39 |
Low | 3.00 |
Bid | 3.06 |
Offer | 3.11 |
Previous close | 3.29 |
Average volume | 2.67m |
---|---|
Shares outstanding | 91.04m |
Free float | 86.55m |
P/E (TTM) | -- |
Market cap | 281.31m USD |
EPS (TTM) | -0.4273 USD |
Data delayed at least 15 minutes, as of May 10 2024 21:00 BST.
More ▼